Literature DB >> 19394032

Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study.

Bryce A Kerlin1, Neal B Blatt, Beng Fuh, Shuang Zhao, Amy Lehman, Carol Blanchong, John D Mahan, William E Smoyer.   

Abstract

OBJECTIVES: To identify clinical variables predictive of the risk of thromboembolism (TE), and to confirm the incidence of TE in primary and secondary childhood nephrotic syndrome (NS). STUDY
DESIGN: A comprehensive chart review identified 326 children with NS from any cause evaluated between 1999 and 2006. These patients had a total of 1472.8 patient-years of follow-up. Comparison statistics, survival analysis, and logistic regression were used to define TE epidemiology and clinical risk factors.
RESULTS: We found that 9.2% of our cohort had experienced at least 1 TE. The overall incidence was 20.4 patients with TEs/1000 patient-years. The median time to the first TE was 70.5 days after diagnosis of NS. Deep venous thrombosis was the most common TE (76%) and was frequently associated with the use of a central venous catheter (45%). Significant independent predictors of TE included age > or = 12 years at onset of NS (P < .0001), severity of proteinuria (P < .0001), and history of TE preceding diagnosis of NS (P < .0001). Life- or limb-threatening TEs represented 23.7% of the events.
CONCLUSIONS: Children with NS should be carefully followed for TE, particularly those who are age 12 years or older, have severe proteinuria, or have a previous history of TE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19394032      PMCID: PMC3685482          DOI: 10.1016/j.jpeds.2009.01.070

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  28 in total

Review 1.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

Authors:  W A Wilson; A E Gharavi; T Koike; M D Lockshin; D W Branch; J C Piette; R Brey; R Derksen; E N Harris; G R Hughes; D A Triplett; M A Khamashta
Journal:  Arthritis Rheum       Date:  1999-07

Review 2.  Thromboembolic risks and complications in nephrotic children.

Authors:  N Schlegel
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

Review 3.  The antiphospholipid syndrome.

Authors:  Massimo Franchini; Dino Veneri
Journal:  Hematology       Date:  2005-08       Impact factor: 2.269

4.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

Review 5.  Systemic lupus erythematosus in children and adolescents.

Authors:  Beth S Gottlieb; Norman T Ilowite
Journal:  Pediatr Rev       Date:  2006-09

6.  Low protein Z levels in children with nephrotic syndrome.

Authors:  Ozan Ozkaya; Kenan Bek; Tunc Fişgin; Yuksel Aliyazicioğlu; Sevinc Sultansuyu; Yonca Açikgöz; Davut Albayrak; Kemal Baysal
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

7.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

8.  Clinical significance of lupus anticoagulants in children.

Authors:  C Male; K Lechner; S Eichinger; P A Kyrle; S Kapiotis; H Wank; A Kaider; I Pabinger
Journal:  J Pediatr       Date:  1999-02       Impact factor: 4.406

9.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients.

Authors:  Jaime Calvo-Alén; Sergio M A Toloza; Mónica Fernández; Holly M Bastian; Barri J Fessler; Jeffrey M Roseman; Gerald McGwin; Luis M Vilá; John D Reveille; Graciela S Alarcón
Journal:  Arthritis Rheum       Date:  2005-07

10.  Detection of antiphospholipid antibodies in children and adolescents.

Authors:  C Kratz; C Mauz-Körholz; H Kruck; D Körholz; U Göbel
Journal:  Pediatr Hematol Oncol       Date:  1998 Jul-Aug       Impact factor: 1.969

View more
  40 in total

1.  Thrombosis of internal jugular vein in nephrotic syndrome presenting as neck pain.

Authors:  Varuna Vyas; Seema Kapoor; Malavika Panda; R N Mandal Ravi
Journal:  Indian J Pediatr       Date:  2012-02-22       Impact factor: 1.967

2.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy.

Authors:  Yoshitsugu Kaku; Yasufumi Ohtsuka; Yasuhiro Komatsu; Toshiyuki Ohta; Takuhito Nagai; Hiroshi Kaito; Shuji Kondo; Yohei Ikezumi; Seiji Tanaka; Shinsuke Matsumoto; Mayumi Sako; Kazushi Tsuruga; Koichi Nakanishi; Koichi Kamei; Hiroshi Saito; Shuichiro Fujinaga; Yuko Hamasaki; Hiroko Chikamoto; Kenji Ishikura; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-02       Impact factor: 2.801

Review 3.  Current and future management of pediatric venous thromboembolism.

Authors:  Bryce A Kerlin
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

4.  Patients with primary membranous nephropathy are at high risk of cardiovascular events.

Authors:  Taewoo Lee; Vimal K Derebail; Abhijit V Kshirsagar; Yunro Chung; Jason P Fine; Shannon Mahoney; Caroline J Poulton; Sophia Lionaki; Susan L Hogan; Ronald J Falk; Daniel C Cattran; Michelle Hladunewich; Heather N Reich; Patrick H Nachman
Journal:  Kidney Int       Date:  2016-02-26       Impact factor: 10.612

5.  Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome.

Authors:  Shannon L Carpenter; Jennifer Goldman; Ashley K Sherman; David T Selewski; Mahmoud Kallash; Cheryl L Tran; Meredith Seamon; Chryso Katsoufis; Isa Ashoor; Joel Hernandez; Katarina Supe-Markovina; Cynthia D'alessandri-Silva; Nilka DeJesus-Gonzalez; Tetyana L Vasylyeva; Cassandra Formeck; Christopher Woll; Rasheed Gbadegesin; Pavel Geier; Prasad Devarajan; William E Smoyer; Bryce A Kerlin; Michelle N Rheault
Journal:  Pediatr Nephrol       Date:  2018-09-07       Impact factor: 3.714

Review 6.  Role of direct oral anticoagulants in patients with kidney disease.

Authors:  Vimal K Derebail; Michelle N Rheault; Bryce A Kerlin
Journal:  Kidney Int       Date:  2019-12-24       Impact factor: 10.612

7.  Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.

Authors:  Bryce A Kerlin; Amanda P Waller; Ruchika Sharma; Melinda A Chanley; Marvin T Nieman; William E Smoyer
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

Review 8.  Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease.

Authors:  Bryce A Kerlin; Rose Ayoob; William E Smoyer
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-16       Impact factor: 8.237

9.  Healthcare burden of venous thromboembolism in childhood chronic renal diseases.

Authors:  Bryce A Kerlin; William E Smoyer; James Tsai; Sheree L Boulet
Journal:  Pediatr Nephrol       Date:  2014-12-07       Impact factor: 3.714

10.  Case series of thromboembolic complications in childhood nephrotic syndrome: Hacettepe experience.

Authors:  Betul Tavil; Fehime Kara; Rezan Topaloglu; Selin Aytac; Sule Unal; Baris Kuskonmaz; Mualla Cetin; Nesrin Besbas; Fatma Gumruk
Journal:  Clin Exp Nephrol       Date:  2014-07-04       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.